LX-1020

N/A

Report date: 2024/10/18 17:38:02

Base Information

Drug NameLX-1020
Drug Alias NameLX-1020
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionApolipoprotein E2 gene transferenceApolipoprotein E4 inhibitors
TargetsApolipoprotein E2Apolipoprotein E4
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLEXEO Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesLexeo Therapeutics IncLEXEO Therapeutics
Inactive CompaniesN/A
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A